Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.67 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27013184 | 0.88 | CRBN (0.52) | CRBNDDB1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL23067572 | 0.81 | CRBN (1.00) | CRBNDDB1 | |
| SCHEMBL23075922 | 0.80 | CRBN (0.60) | CRBNDDB1 | |
| SCHEMBL23075901 | 0.78 | CRBN (0.67) | CRBNDDB1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL23075740 | 0.78 | CRBN (0.67) | CRBNDDB1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL23075917 | 0.77 | CRBN (0.69) | CRBNDDB1 | |
| SCHEMBL27013182 | 0.76 | CRBN (0.52) | CRBNDDB1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL23075771 | 0.76 | CRBN (0.65) | CRBNDDB1ALDH1A1 | |
| SCHEMBL23075760 | 0.74 | CRBN (0.58) | CRBNDDB1ALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL23075766 | 0.74 | CRBN (0.63) | CRBNDDB1ALDH1A1SMN1; SMN2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-11623929-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20210070763-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070763-A1 | SPIROCYCLIC COMPOUNDS | CRBN, XIAP, RBX1 | CRBN 1/4885DDB1 153/4885L3MBTL1 2113/4885 |
| US-20240018156-A1 | SPIROCYCLIC COMPOUNDS | CRBN, XIAP, RBX1 | CRBN 1/4885DDB1 153/4885L3MBTL1 2113/4885 |
| US-11623929-B2 | Spirocyclic compounds | CRBN, XIAP, RBX1 | CRBN 1/4885DDB1 153/4885L3MBTL1 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.